** Shares of drug distributor Cencora COR.N rise 5.7% to $307.50
** Co raises annual adj.profit forecast on strong demand for costly specialty medicines and weight-loss drugs
** Expects 2025 adj.profit to be between $15.70 and $15.95 per share, up from its previous expectation of $15.30 to $15.60 per share
** Q2 revenue at its U.S. healthcare business came in at $68.3 billion, up 11.4% from a year earlier
** Reports Q2 adj.profit of $4.42 per share, beating analysts' estimates of $4.11 per share, as per data compiled by LSEG
** "The fact that COR has now increased guidance 4x so far in FY25 (this is only the second fiscal quarter report) shows underlying confidence in the business as well"- brokerage Leerink Partners
** Including session moves, stock up 36.6% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。